Stage 1 small cell cancer of the vagina

Haykal, Tarek; Pandit, Trailokya; Bachuwa, Ghassan; Danish, Rizwan

doi:10.1136/bcr-2018-225294

Cited by 5 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 5 cases were reported to be tested for HPV: 1 negative, 7 1 positive for a high-risk type different to 16–18 (not specified), 13 and 3 positive for 18 type (2 cases reported in 2021 6 and our case). The 3 cases HPV18+ positive were reported to be p16+ with a diffuse pattern in the immunochemistry study.…”

Section: Resultsmentioning

confidence: 98%

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm

Capote

Doménech

Valdivieso

et al. 2022

J Low Genit Tract Dis

View full text Add to dashboard Cite

ObjectivesSmall cell carcinoma of the vagina (SmCCV) is an extremely rare disease. Evidence-based data and specific guidelines are lacking. We conducted the first systematic review of case reports to provide the most overall picture of SmCCV.Materials and MethodsLiterature search in PubMed and Scopus was performed using the terms “small cell carcinoma” and “vagina.” English-language case reports of primary SmCCV up to January 2022 were included.ResultsTwenty-nine articles describing 44 cases met our inclusion criteria. We report a new case of our hospital. The global median overall survival (mOS) was 12.00 months (95% CI = 9.31–14.69). The mOS was not reached for stage I, and it was 12.00, 12.00, 9.00, and 8.00 months for stages II, III, IVA, and IVB, respectively (statistically significant differences between stage I and stages II, III, or IVA [log rank p = .003–.017]). Thirty-five cases received local treatments (77.8%). The mOS of patients treated with surgery ± complementary chemotherapy, radiotherapy ± complementary chemotherapy, chemoradiation ± complementary chemotherapy, and surgery + radiotherapy ± complementary chemotherapy were 11.00, 12.00, 17.00, and 29.00 months, respectively. The use of adjuvant or neoadjuvant chemotherapy (64.5%, mostly platinum + etoposide) showed longer mOS (77.00 vs 15.00 months). Four of 5 tested cases presented human papillomavirus infection, 3 of them presenting type 18.ConclusionsSmall cell carcinoma of the vagina shows dismal prognosis. Multimodal local management plus complementary chemotherapy seems to achieve better outcomes. Human papillomavirus could be related to the development of SmCCV. A diagnostic-therapeutic algorithm is proposed.

show abstract

Section: Resultsmentioning

confidence: 98%

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm

Capote

Doménech

Valdivieso

et al. 2022

J Low Genit Tract Dis

View full text Add to dashboard Cite

show abstract

“…Only 1 case of primary vaginal SCNEC has been previously reported to be positive for high-risk HPV, but not for HPV16 and HPV18. 5 In this study, we present the first case report of an HPV18-positive primary vaginal SCNEC, with a description of the cancer genome profiles investigated using NSG analysis.…”

Section: Discussionmentioning

confidence: 99%

Human Papilloma Virus 18-Positive Submucosal Small Cell Neuroendocrine Carcinoma of the Vagina: An Immunohistochemical and Genomic Study

et al. 2021

View full text Add to dashboard Cite

Primary vaginal neuroendocrine carcinoma (NEC) is extremely rare among female genital tract tumors. Here, we report 2 cases of vaginal small cell NEC (SCNEC) using immunohistochemistry and next-generation sequencing (NGS) analysis. The 2 patients were in their mid-to-late 70s, presented with abnormal vaginal bleeding and had a vaginal submucosal mass. The biopsied or resected tumors showed a typical neuroendocrine morphology consisting of solid nests of atypical tumor cells, with no specific organoid patterns, and proliferating in the vaginal submucosa. Immunohistochemical analysis showed strong and diffuse expression of chromogranin A, synaptophysin, and p16, but no thyroid transcription factor 1 expression. Additionally, both cases were positive for human papillomavirus (HPV) 18. An NGS-based cancer panel analysis revealed that the tumors carried NF1 and AR mutations, but no major driver mutations were detected. The results of this study suggested that HPV18 infection is linked to vaginal SCNEC.

show abstract

“…106 Although it has been well known that SCNECCs are associated with high-risk HPV, mostly HPV 16 and 18 infections, the correlation between HPV and small-cell carcinoma of other genital tract areas is in doubt. 120 However, based on the recent systematic review by Capote et al, four of the five tested cases presented HPV, with three of them presenting type 18. 112 It is not shown that involvement of a particular vaginal segment or amount of vaginal surface area involved with the tumor affects patients' outcome.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Small‐cell neuroendocrine carcinoma of the female genital tract: A comprehensive overview

Saraei,

Heshmati,

Hosseini

2024

J Neuroendocrinology

View full text Add to dashboard Cite

Small‐cell neuroendocrine carcinomas (SCNECs) of the female genital tract are rare and aggressive tumors that are characterized by a high rate of recurrence and poor prognosis. They can arise from various sites within the female genital tract, including the cervix, endometrium, ovary, fallopian tube, vagina, and vulva. They are composed of cells with neuroendocrine features, such as the ability to produce and secrete hormones and peptides, and a high mitotic rate. Immunohistochemical staining for neuroendocrine markers, such as chromogranin A, synaptophysin, and CD56, can aid in the diagnosis of these tumors. This article provides an overview of the epidemiology, etiology, and risk factors associated with these tumors, as well as their clinical presentation, cellular characteristics, diagnosis, and finally the current treatment options for SCNECs, including surgery, chemotherapy, and radiation therapy, alone or in combination.

show abstract

Stage 1 small cell cancer of the vagina

Cited by 5 publications

References 6 publications

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm

Small Cell Carcinoma of the Vagina: First Systematic Review of Case Reports and Proposal of a Management Algorithm

Human Papilloma Virus 18-Positive Submucosal Small Cell Neuroendocrine Carcinoma of the Vagina: An Immunohistochemical and Genomic Study

Small‐cell neuroendocrine carcinoma of the female genital tract: A comprehensive overview

Contact Info

Product

Resources

About